MedTrace Logo

An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis

NCT01609049 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1496

Last updated 2017-04-12

No results posted yet for this study

Summary

This prospective observational study will evaluate the efficacy and safety of peginterferon alfa-2a in combination with ribavirin in participants with chronic hepatitis C, including participants with compensated liver cirrhosis, in clinical practice.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

Peginterferon alfa-2a

Administration of treatment will be according to local recommendation under local labeling.

DRUG

Ribavirin

Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-07
Primary Completion
2015-06-22
Completion
2015-06-22

Countries

  • Russia
  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01609049 on ClinicalTrials.gov